EA201071086A1 - Усовершенствованный способ получения вакцинных антигенов вируса гриппа - Google Patents

Усовершенствованный способ получения вакцинных антигенов вируса гриппа

Info

Publication number
EA201071086A1
EA201071086A1 EA201071086A EA201071086A EA201071086A1 EA 201071086 A1 EA201071086 A1 EA 201071086A1 EA 201071086 A EA201071086 A EA 201071086A EA 201071086 A EA201071086 A EA 201071086A EA 201071086 A1 EA201071086 A1 EA 201071086A1
Authority
EA
Eurasian Patent Office
Prior art keywords
virus
vaccine antigens
advanced method
obtaining vaccine
obtaining
Prior art date
Application number
EA201071086A
Other languages
English (en)
Inventor
Кристоф Хауссманн
Франк Хаусшильд
Бьерн Йобст
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41091288&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201071086(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA201071086A1 publication Critical patent/EA201071086A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C12N2760/16163—Methods of inactivation or attenuation by chemical treatment

Abstract

Раскрыт ряд усовершенствований для получения вакцинных антигенов из разрушенных вирусов гриппа. За стадией расщепления может следовать замена детергента. Расщепление может происходить в присутствии буфера с высокой ионной силой и/или в присутствии фосфатного буфера.
EA201071086A 2008-03-18 2009-03-18 Усовершенствованный способ получения вакцинных антигенов вируса гриппа EA201071086A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6986808P 2008-03-18 2008-03-18
PCT/IB2009/005122 WO2009115917A2 (en) 2008-03-18 2009-03-18 Improvements in preparation of influenza virus vaccine antigens

Publications (1)

Publication Number Publication Date
EA201071086A1 true EA201071086A1 (ru) 2011-04-29

Family

ID=41091288

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201071086A EA201071086A1 (ru) 2008-03-18 2009-03-18 Усовершенствованный способ получения вакцинных антигенов вируса гриппа

Country Status (11)

Country Link
US (3) US20110014230A1 (ru)
EP (3) EP2889042A3 (ru)
JP (1) JP5518041B2 (ru)
KR (1) KR20100135766A (ru)
CN (1) CN101998990B (ru)
AU (1) AU2009227674C1 (ru)
CA (1) CA2718430A1 (ru)
EA (1) EA201071086A1 (ru)
ES (1) ES2535101T3 (ru)
NZ (1) NZ587798A (ru)
WO (1) WO2009115917A2 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11707520B2 (en) * 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
GB0905570D0 (en) * 2009-03-31 2009-05-13 Novartis Ag Combined vaccines
GB0918830D0 (en) * 2009-10-27 2009-12-09 Glaxosmithkline Biolog Niederl Process
US9555093B2 (en) 2010-04-30 2017-01-31 Temasek Life Sciences Laboratory Limited Universal vaccine against H5N1 lineages
US9821051B1 (en) 2010-10-28 2017-11-21 Seqirus UK Limited Reducing hospitalization in elderly influenza vaccine recipients
KR20160096215A (ko) * 2011-07-20 2016-08-12 애보트 바이올로지컬스 비.브이. 바이러스 항원 및 백신의 제조 방법
JP6136236B2 (ja) * 2012-12-19 2017-05-31 東ソー株式会社 組換えタンパク質の精製方法
FR3025107B1 (fr) 2014-08-29 2018-10-05 Calixar Procede de preparation d'un antigene vaccinal, antigene vaccinal obtenu et utilisations
RU2710239C1 (ru) * 2019-06-14 2019-12-25 Федеральное государственное унитарное предприятие "Санкт-Петербургский научно-исследовательский институт вакцин и сывороток и предприятие по производству бактерийных препаратов" Федерального медико-биологического агентства Способ получения антигена или антигенов для производства противогриппозной вакцины и вакцина на его основе
JP2023500873A (ja) * 2019-11-07 2023-01-11 セキラス ユーケー リミテッド 低減した粒度を有するウイルスワクチンを生成するための組成物および方法
RU2741003C1 (ru) * 2020-03-27 2021-01-22 Евгений Дмитриевич Некрасов Способ производства четырехвалентной субъединичной вакцины против гриппа без адъювантов

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3316153A (en) * 1965-03-29 1967-04-25 Lilly Co Eli Virus purification
AU405949B1 (en) 1966-02-24 1970-09-18 The Australian National University Influenza virus sub-unit vaccine
US3962421A (en) * 1973-06-18 1976-06-08 American Home Products Corporation Method for the disruption of lipid-containing viruses
US4158054A (en) 1973-10-18 1979-06-12 Duncan Flockhart & Co. Ltd. Preparation of virus sub-unit vaccines
US4140762A (en) 1974-01-14 1979-02-20 Sandoz Ltd. Influenza sub-unit vaccine
US4064232A (en) 1974-01-14 1977-12-20 Sandoz Ltd. Process for isolating the immunogenic components of influenza viruses
US4060082A (en) 1976-08-16 1977-11-29 Mpl, Inc. Dual-ingredient medication dispenser
DE2816086C3 (de) 1978-04-13 1985-04-25 Sartorius GmbH, 3400 Göttingen Asymmetrische Ultrafiltrationsmembrane auf der Basis von Zellulosetriacetat
US4327182A (en) 1981-01-22 1982-04-27 Connaught Laboratories Incorporated Purification of influenza sub-unit vaccine
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US5011828A (en) 1985-11-15 1991-04-30 Michael Goodman Immunostimulating guanine derivatives, compositions and methods
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
AU627226B2 (en) 1988-08-25 1992-08-20 Liposome Company, Inc., The Influenza vaccine and novel adjuvants
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US4988815A (en) 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
US5658731A (en) 1990-04-09 1997-08-19 Europaisches Laboratorium Fur Molekularbiologie 2'-O-alkylnucleotides as well as polymers which contain such nucleotides
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
EP0872478B1 (en) 1991-03-01 2002-12-18 Minnesota Mining And Manufacturing Company Intermediates for the preparation of 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
JPH0614756Y2 (ja) 1991-06-26 1994-04-20 株式会社アルテ 組み立て式の２室式容器兼用注射器
US5936076A (en) 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
EP0570826A1 (de) 1992-05-20 1993-11-24 Akzo Nobel N.V. Celluloseacetatmembranen
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
WO1994019013A1 (en) * 1993-02-19 1994-09-01 Smithkline Beecham Corporation Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
JP4028593B2 (ja) 1993-03-23 2007-12-26 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム ３−ｏ脱アシル化モノホスホリルリピドａ含有ワクチン組成物
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
WO1995002597A1 (en) 1993-07-15 1995-01-26 Minnesota Mining And Manufacturing Company IMIDAZO[4,5-c]PYRIDIN-4-AMINES
AU5543294A (en) 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US5522991A (en) 1994-07-20 1996-06-04 Millipore Investment Holdings Limited Cellulosic ultrafiltration membrane
FR2723740B1 (fr) 1994-08-16 1996-11-08 Pasteur Merieux Serums Vacc Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications
US5496284A (en) 1994-09-27 1996-03-05 Waldenburg; Ottfried Dual-chamber syringe & method
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
UA56132C2 (ru) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиция вакцины (варианты), способ стабилизации qs21 по отношению к гидролизу (варианты), способ приготовления вакцины
DE19612967A1 (de) 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
WO1998001174A1 (fr) 1996-07-05 1998-01-15 Debiotech S.A. Seringue a chambre double permettant le melange de deux produits avant leur injection
WO1998040100A1 (en) 1997-03-10 1998-09-17 Ottawa Civic Loeb Research Institute USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
US5971953A (en) 1998-01-09 1999-10-26 Bachynsky; Nicholas Dual chamber syringe apparatus
WO1999017820A1 (en) 1997-10-03 1999-04-15 Texas Pharmaceuticals, Inc. Improved dual chamber syringe apparatus
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
CN101219217A (zh) 1998-05-07 2008-07-16 科里克萨有限公司 佐剂组合物及其使用方法
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
DE19835749C1 (de) 1998-08-07 2000-02-03 Dieter Perthes Fertig-Spritze für nicht-stabile Arzneimittel
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
HU228473B1 (en) 1998-10-16 2013-03-28 Smithkline Beecham Biolog Adjuvant systems and vaccines
EP1140164B1 (en) * 1998-12-17 2009-02-11 Sanofi Pasteur Limited Multivalent immunogenic composition containing rsv subunit composition and influenza virus preparation
US20030130212A1 (en) 1999-01-14 2003-07-10 Rossignol Daniel P. Administration of an anti-endotoxin drug by intravenous infusion
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
DE60013773T2 (de) 1999-02-03 2005-11-10 Biosante Pharmaceuticals, Inc. Methoden zur Herstellung von therapeutischen Kalziumphosphat Partikeln
DK2345716T3 (en) 1999-04-06 2015-02-09 Wisconsin Alumni Res Found RECOMBINANT INFLUENZAVIRA FOR VACCINES AND GENTHERAPY
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
WO2001004333A1 (en) 1999-07-14 2001-01-18 Mount Sinai School Of Medicine Of New York University In vitro reconstitution of segmented negative-strand rna viruses
CA2383105C (en) 1999-09-24 2010-01-26 Smithkline Beecham Biologicals S.A. Intranasal influenza virus vaccine
CN1454091A (zh) 1999-09-25 2003-11-05 衣阿华大学研究基金会 免疫刺激性核酸
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
EP1103610A1 (en) * 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
US20010044416A1 (en) 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
ES2267724T3 (es) * 2000-02-15 2007-03-16 Id Biomedical Corporation Of Quebec Vacuna antigripal basada en proteosomas.
CA2401117C (en) 2000-03-03 2010-06-29 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell
ATE420189T1 (de) 2000-04-28 2009-01-15 St Jude Childrens Res Hospital Dna-transfektionssystem zur erzeugung von infektiösen negativsträngigen rna virus
FR2808803B1 (fr) 2000-05-11 2004-12-10 Agronomique Inst Nat Rech Cellules es modifiees et gene specifique de cellules es
AU2001293233A1 (en) 2000-09-01 2002-03-13 Chiron Corporation Aza heterocyclic derivatives and their therapeutic use
BRPI0113757B8 (pt) 2000-09-11 2017-11-07 Chiron Corp derivados de quinolinona como inibidores de tirosina quinase
ES2298269T3 (es) 2000-09-26 2008-05-16 Idera Pharmaceuticals, Inc. Modulacion de la actividad inmunoestimulante de analogos oligonucleotidicos inmunoestimulantes mediante cambios quimicos posicionales.
GB0024089D0 (en) 2000-10-02 2000-11-15 Smithkline Beecham Biolog Novel compounds
US6660747B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6664260B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
UA74852C2 (en) 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6660735B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6677347B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
WO2002067983A1 (en) 2001-02-23 2002-09-06 Glaxosmithkline Biologicals S.A. Novel vaccine
EP1361890B1 (en) 2001-02-23 2011-03-30 GlaxoSmithKline Biologicals s.a. Influenza vaccine formulations for intradermal delivery
TWI228420B (en) * 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
FR2832423B1 (fr) 2001-11-22 2004-10-08 Vivalis Systeme d'expression de proteines exogenes dans un systeme aviaire
US7321033B2 (en) 2001-11-27 2008-01-22 Anadys Pharmaceuticals, Inc. 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
OA12729A (en) 2001-11-27 2006-06-28 Anadys Pharmaceuticals Inc 3-Beta-D ribofuranosylthiazoloÄ4,5-dÜpyridimine nucleosides and uses thereof.
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
ATE447404T1 (de) 2002-03-29 2009-11-15 Novartis Vaccines & Diagnostic Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
AU2003233519A1 (en) 2002-05-29 2003-12-19 3M Innovative Properties Company Process for imidazo(4,5-c)pyridin-4-amines
CA2493690C (en) 2002-06-13 2011-11-08 New York University Synthetic c-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases
US7250443B2 (en) 2002-08-23 2007-07-31 Chiron Corporation Pyrrole based inhibitors of glycogen synthase kinase 3
EP1587473A4 (en) 2002-12-27 2008-08-13 Novartis Vaccines & Diagnostic THIOSEMICARBAZONES ANTIVIRAL AND IMMUNOSTIMULANTS
CA2513655C (en) 2003-01-21 2011-11-22 Chiron Corporation Use of tryptanthrin compounds for immune potentiation
GB0301554D0 (en) 2003-01-23 2003-02-26 Molecularnature Ltd Immunostimulatory compositions
EP2258365B1 (en) 2003-03-28 2013-05-29 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
RU2236257C1 (ru) 2003-09-15 2004-09-20 Косяков Константин Сергеевич Синтетический иммуноген для терапии и профилактики злоупотреблений наркотическими и психоактивными веществами
US7771726B2 (en) 2003-10-08 2010-08-10 New York University Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
WO2005089837A1 (ja) 2004-03-23 2005-09-29 Nipro Corporation プレフィルドシリンジ
CN1964626A (zh) 2004-03-31 2007-05-16 纽约大学 新型合成c－糖脂、其合成及其治疗传染病、癌症和自身免疫性疾病的用途
KR20110132416A (ko) 2004-04-05 2011-12-07 화이자 프로덕츠 인코포레이티드 미세유체화된 수중유 유화액 및 백신 조성물
WO2005113756A1 (en) 2004-05-14 2005-12-01 Glaxosmithkline Biologicals S.A. Method
JP2007537760A (ja) 2004-05-20 2007-12-27 アイディー バイオメディカル コーポレイション インフルエンザワクチンを製造するためのプロセス
RS51665B (en) 2004-09-09 2011-10-31 Novartis Vaccines And Diagnostics Gmbh. Reduction of potential iatrogenic risks associated with influenza vaccines
ES2526170T3 (es) 2004-12-23 2015-01-07 Medimmune, Llc Línea celular MDCK no tumorigénica para propagar virus
NZ556061A (en) 2004-12-24 2009-06-26 Solvay Biologicals Bv Rescue of influenza virus
EP1861120B1 (en) * 2005-03-23 2016-05-25 GlaxoSmithKline Biologicals S.A. Use of an influenza virus and an oil-in-water emulsion adjuvant to induce cd4 t-cell and/or improved b-memory cell response
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
CN101257919B (zh) 2005-08-05 2012-08-29 国立大学法人德岛大学 可以由选择性产生IgA抗体向产生IgA和IgG两种抗体转换的抗原药物载体和使用该载体的经鼻·粘膜疫苗
ES2525518T3 (es) * 2005-11-01 2014-12-26 Novartis Vaccines And Diagnostics Gmbh Vacunas virales derivadas de células con niveles reducidos de ADN celular residual
JP2009514839A (ja) * 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル サイトカイン誘導剤を含むアジュバントインフルエンザワクチン
EA014028B1 (ru) * 2005-11-04 2010-08-30 Новартис Вэксинс Энд Диагностикс Срл Эмульсии, содержащие свободное поверхностно-активное вещество в водной фазе в качестве адъюванта сплит вакцин против гриппа
EP1945253A2 (en) * 2005-11-04 2008-07-23 Novartis Vaccines and Diagnostics S.r.l. Adminstration routes for priming/boosting with influenza vaccines
EP1951300B1 (en) * 2005-11-04 2011-06-22 Novartis Vaccines and Diagnostics S.r.l. Changing th1/th2 balance in split influenza vaccines with adjuvants
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
WO2007085969A2 (en) 2006-01-27 2007-08-02 Novartis Vaccines And Diagnostics Gmbh & Co Kg Influenza vaccines containing hemagglutinin and matrix proteins
ES2539514T3 (es) 2006-04-19 2015-07-01 Medimmune, Llc Métodos y composiciones para expresar ARN viral de sentido negativo en células de canino
EP2032163B1 (en) * 2006-06-15 2013-01-23 Novartis AG Adjuvant-sparing multi-dose influenza vaccination regimen
US20080014217A1 (en) * 2006-07-17 2008-01-17 Emmanuel Jules Hanon Influenza vaccine
PL2043682T3 (pl) 2006-07-17 2014-09-30 Glaxosmithkline Biologicals Sa Szczepionka przeciw grypie
GB0614460D0 (en) * 2006-07-20 2006-08-30 Novartis Ag Vaccines
CN1911445B (zh) 2006-08-11 2013-04-17 深圳市孚沃德生物技术有限公司 流行性感冒原代地鼠肾细胞多价疫苗及其制备方法
EA015817B1 (ru) 2006-10-12 2011-12-30 Глаксосмитклайн Байолоджикалс С.А. Иммуногенная композиция, содержащая адъювант в виде эмульсии "масло в воде"

Also Published As

Publication number Publication date
CN101998990A (zh) 2011-03-30
AU2009227674C1 (en) 2015-01-29
JP2011515387A (ja) 2011-05-19
US20160158341A1 (en) 2016-06-09
WO2009115917A3 (en) 2010-02-04
EP2268309A2 (en) 2011-01-05
AU2009227674A1 (en) 2009-09-24
KR20100135766A (ko) 2010-12-27
CN101998990B (zh) 2013-11-27
US20110014230A1 (en) 2011-01-20
CA2718430A1 (en) 2009-09-24
US20210205438A1 (en) 2021-07-08
NZ587798A (en) 2013-06-28
US10946088B2 (en) 2021-03-16
EP2889042A2 (en) 2015-07-01
WO2009115917A2 (en) 2009-09-24
AU2009227674B2 (en) 2014-10-16
ES2535101T3 (es) 2015-05-05
EP3459563A1 (en) 2019-03-27
JP5518041B2 (ja) 2014-06-11
EP2889042A3 (en) 2015-10-14
EP2268309B1 (en) 2015-01-21

Similar Documents

Publication Publication Date Title
EA201071086A1 (ru) Усовершенствованный способ получения вакцинных антигенов вируса гриппа
MX2021006342A (es) Mutantes de virus de influenza y usos para los mismos.
CY1119284T1 (el) ΣΩΜΑΤΙΔΙΑ ΠΑΡΟΜΟΙΑ ΜΕ ΙΟ ΓΛΥΚΟ-ΠΡΩΤΕΪΝΗΣ ΛΥΣΣΑΣ (VLPs)
EA201390856A1 (ru) Инактивация вирусов с применением улучшенного способа растворитель-детергент
CY1111378T1 (el) Προερχομενα απο κυτταρα ιικα εμβολια με χαμηλα επιπεδα υπολειμματικου κυτταρικου dna
WO2010132604A3 (en) Neutralizing molecules to influenza viruses
WO2009121004A3 (en) Neutralizing molecules to viral antigens
EA201391170A1 (ru) Терапевтическое средство на основе дрожжей для лечения хронического гепатита b
EA201591888A1 (ru) Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов
CL2011002082A1 (es) Composicion farmaceutica que comprende un inhibidor de nucleosido polimerasa y un inhibidor de proteasa macrociclica; proceso para preparar dicha composicion farmaceutica; metodo para tratar o mejorar una infeccion con virus de la hepatitis c, fibrosis hepatica y alteracion de la funcion hepatica.
MX352604B (es) Composiciones inmunogenicas de la glucoproteina g de los virus hendra y nipah.
EA201391515A1 (ru) Инактивированная вакцина вируса денге
BR112012033767A2 (pt) processo para produzir um vírus de interesse, para remover um agente adventício, e para remover um agente adventício, vírus,e, composição imunogênica ou vacina.
EA201390806A1 (ru) Конструкция пептидного каркаса
WO2008156778A3 (en) Influenza m2 protein mutant viruses as live influenza attenuated vaccines
MX2009006469A (es) Metodo de duplicacion del virus de la influenza en cultivo.
CL2011001993A1 (es) Composicion inmunogenica que comprende al menos un antigeno del virus del dengue inactivado y un adyuvante sin aluminio; metodo de produccion; y su uso para prevenir, mejorar o tratar una enfermedad productiva por el virus del dengue en un sujeto.
EA201001045A1 (ru) Модифицированный вирус гриппа
EP2078083A4 (en) NEW DOG INFLUENZA VIRUS AND VEGETABLE THEREFOR
ES2682981T3 (es) Proteínas de hemaglutinina del virus de la gripe y método de uso de las mismas
MX2012009046A (es) Composiciones y metodos de inmunizacion.
ME01140B (me) Virus goveđe virusne dijareje s modifikovanim erns proteinom
EA201290897A1 (ru) Вакцины для пандемического гриппа
BR112013016503A2 (pt) composições e método de vacina de vírus da diarreia viral bovina tipo 1b.
MX359103B (es) Composiciones y sus usos en el tratamiento de infecciones virales.